StreetAlpha.app
Home › Stocks › INVA

Innoviva, Inc. (INVA)

Healthcare
$18.30
▼ −1.03%
LAST CLOSE · NOV 17

Innoviva is a Burlingame, California biopharmaceutical company that earns royalties on lung medicines and sells hospital critical care and antibiotic drugs. It last closed at $18.30 on Nov 17, down 1.03% on the day.

AI Auto Pilots
Is INVA in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$438.3M
+12.8% vs a year ago
Net income
$193.4M
+51.9% vs a year ago
EPS (diluted)
$2.35
+41.6% vs a year ago
Free cash flow
$182.5M
41.6% margin
Valuation
Market cap
$1.3B
71.1M shares
P/E
7.8
Price over 12 month EPS
Price to sales
3.0
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$581.4M
At Sep 30
Debt
$258.8M
At Sep 30
Shareholder equity
$1.1B
Buybacks
$81.9M
Last 12 months
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $391.9M$391.9MFY2021FY2022: $331.3M$331.3MFY2022FY2023: $310.5M$310.5MFY2023FY2024: $358.7M$358.7MFY2024FY2025: $411.3M$411.3MFY2025

From INVA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated INVA in the past 90 days, not enough for a consensus
Average 12-month target
$34.00
▲ 85.8% upside

Based on 1 analyst who set a price target on INVA in the past 90 days. The average target is $34.00, with a high of $34.00 and a low of $34.00, compared with the last close of $18.30.

Low $34.00Avg $34.00High $34.00
Blue marker: last close $18.30
Highest target$34.00
Average target$34.00
Lowest target$34.00
Latest rating changes
OppenheimerTarget lowered
Nov 5Buy$35 → $34
OppenheimerAssumed coverage
Sep 23Buy$35
Cantor FitzgeraldMaintained
Aug 7Buy$34
BTIGMaintained
Jun 22Buy$42
HC Wainwright & Co.Reiterated
Jun 1Buy$46
DateFirmActionRatingPrice target
Nov 5OppenheimerTarget loweredBuy$35 → $34
Sep 23OppenheimerAssumed coverageBuy$35
Aug 7Cantor FitzgeraldMaintainedBuy$34
Jun 22BTIGMaintainedBuy$42
Jun 1HC Wainwright & Co.ReiteratedBuy$46
Loading…

Technical Analysis

INVA · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 10% below its 20 day and 12% below its 50 day average. It is 19% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 27), oversold. The nearest support is the 52 week low at $18.28, and the nearest resistance the Pivot at $18.39.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 3.4%/day
Key levels
$25.1552 week high+37.4%
$21.87200 day average+19.5%
$21.33Swing high (Aug 26)+16.6%
$21.00100 day average+14.8%
$20.5850 day average+12.5%
$20.0820 day average+9.7%
$18.49Pivot R1+1.0%
$18.39Pivot+0.5%
$18.30Last close
$18.2852 week low−0.1%
$18.19Pivot S1−0.6%
Indicators
RSI (14)27.34Oversold below 30Oversold
MACD-0.64Below its signal lineBearish
Stochastic5.2Near the bottom of its rangeOversold
ADX (14)23.4Weak trend
Williams %R-99.4Oversold below −80, overbought above −20Oversold
CCI (20)-120.6Oversold below −100, overbought above 100Oversold
Rate of change−12.6%Change over 10 sessionsBearish
ATR (14)$0.62Typical daily range, 3.4% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for INVA

What happened before

See how INVA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow INVA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How INVA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in INVA in the last 90 days.

Loading…

See today’s whale options flow across the market →

INVA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bearish
Strongly bearishNeutralStrongly bullish
  • ●151 buying vs 151 selling
  • ▼Held by funds -1.3 pts
  • ▼Funds holding -17
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding294311−5.5%
In funds' top 10110.0%
Held by funds104.8%106.0%−1.3 pts
New / increased38 / 11345 / 132−14.7%
Reduced / sold out95 / 5684 / 22+42.5%
Put/call ratio0.63––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See INVA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether INVA is in one of them and how their past INVA trades turned out.

INVA in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered INVA in an article yet. Here's the latest on the wider market.

INVA Congress Trades

All congress trades →
Trades, 12 months
2
Buys
1
50%
Sells
1
50%
People
1
Last filed Sep 22
Who traded INVA · since 2025
Latest 4 filings
$15K – $50KTraded Jul 29, 2026Filed Sep 22, 2026
$15K – $50KTraded Jan 30, 2026Filed May 14, 2026
$250K – $500KTraded Mar 25, 2025Filed Apr 23, 2025
$50K – $100KTraded Mar 24, 2025Filed Apr 23, 2025
PersonTypeAmountTradedFiledDelay
Donald J TrumpExecutive branchSell$15K – $50KJul 29, 2026Sep 22, 202655 d
Donald J TrumpExecutive branchBuy$15K – $50KJan 30, 2026May 14, 2026104 d
George WhitesidesD · CASell$250K – $500KMar 25, 2025Apr 23, 202529 d
George WhitesidesD · CASell$50K – $100KMar 24, 2025Apr 23, 202530 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Innoviva

Innoviva is a biopharmaceutical company based in Burlingame, California. It earns royalties on inhaled medicines for asthma and chronic lung disease that GSK develops and sells. It also markets hospital medicines for critical care and serious bacterial infections, such as treatments for septic shock and pneumonia, which are used by hospitals and their patients. The company also holds stakes in other healthcare companies.

Headquarters
Burlingame, CA